PARP1 and neoplasm: It increases the lifetime risk of certain types of cancer development, especially breast and ovarian cancers, but paradoxically the HRD in the tumor cells makes the cancer susceptible to therapy by poly (ADP-ribose) polymerase (PARP) inhibitors and platinum compounds.